Here's Why Acadia Pharmaceuticals Jumped 30.1% in September

Acadia Pharmaceuticals (NASDAQ: ACAD) jumped 30.1% in September, according to data provided by S&P Global Market Intelligence, after the company reported positive results for the phase 3 Harmony clinical trial testing its antipsychotic Nuplazid in patients with dementia.

Part of the large jump in the stock price comes from a lack of confidence in Nuplazid after the drug failed a late-stage clinical trial in schizophrenia patients who weren't getting an adequate response to their current therapy. The success in the Harmony study could be the different patient population or it could have to do with the study design since psychiatric drugs have notoriously high placebo effects.

Image source: Getty Images.

Continue reading

Source Fool.com